Invention Grant
- Patent Title: MIR-21 promoter driven targeted cancer therapy
-
Application No.: US13145332Application Date: 2010-01-19
-
Publication No.: US08492133B2Publication Date: 2013-07-23
- Inventor: Rina Rosin-Arbesfeld , Ella Sklan , Alona Zilberberg , Naama David
- Applicant: Rina Rosin-Arbesfeld , Ella Sklan , Alona Zilberberg , Naama David
- Applicant Address: IL Tel Aviv
- Assignee: Ramot at Tel Aviv University, Ltd.
- Current Assignee: Ramot at Tel Aviv University, Ltd.
- Current Assignee Address: IL Tel Aviv
- Agency: Greenberg Traurig, LLP
- International Application: PCT/IL2010/000049 WO 20100119
- International Announcement: WO2010/084488 WO 20100729
- Main IPC: C12N15/85
- IPC: C12N15/85
Abstract:
The invention provides a nucleic acid construct comprising a promoter sequence derived from microRNA-21 (miR-21) linked to a nucleic acid sequence encoding an anti-cancer agent, an example of which is a toxin. The constructs of the invention are particularly useful for treating tumors expressing miR-21.
Public/Granted literature
- US20120065251A1 MIR-21 PROMOTER DRIVEN TARGETED CANCER THERAPY Public/Granted day:2012-03-15
Information query
IPC分类:
